Register
|
Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | ESMO 2018 Congress
Specialties >>
Acute Myeloid Leukemia
Biosimilars
Bladder Cancer
Brain Cancer
Breast Cancer
Chronic Lymphocytic Leukemia
Colorectal Cancer
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Gastric Cancer
Gastrointestinal Cancers
Genitourinary Cancers
Gynecologic Cancers
Head and Neck Cancers
Hematology
Hepatocellular Carcinoma
Immunotherapy
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
Multiple Myeloma
Myeloproliferative Neoplasms
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Skin Cancers
Soft Tissue Sarcoma
Thyroid Cancers
Partners >>
Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up
Latest News
MORE >>
FLT3 Inhibitors Shake Up Treatment Landscape for AML
November 21, 2018
Mary-Beth Percival, MD, discusses the ongoing development of FLT3 inhibitors and other current research in patients with AML.
Read more >>
Feature:
Brentuximab Vedotin Granted FDA Approval for Frontline CD30+ PTCL
Learn More >>
Glasdegib Granted FDA Approval for AML
November 21, 2018
Frontline Venetoclax Granted Accelerated FDA Approval for Older Patients With AML
November 21, 2018
VR-CAP Regimen Improves Survival Over R-CHOP in Mantle Cell Lymphoma
November 21, 2018
Chari Reviews Treatment Options in 2 Case Studies of Patients With Multiple Myeloma
November 21, 2018
Videos
Rationale for Combination Therapy in Multiple Myeloma
Promising Data for LOXO-292 in Thyroid Cancers
Using Antibody-Drug Conjugates for Treatment of AML
Overcoming Challenges in Treating MCL
Case Studies
Elucidating a Case of Locally Advanced CSCC
Prognosis for Stage IV Hodgkin's Lymphoma & Patient Expectations
Managing Extranodal MZL
Impressions of a Case of Stage 4 GEJ Cancer
Latest Journal
All Journals >>
Targeted Therapies in Oncology
November 2018
What Is the Role of SCT as Novel Agents Emerge for Relapsed/Refractory HL?
Small Molecule Inhibitors Prove Effective in Targeting NHL
MORE >>
Most Popular
Case 1: Immunotherapy in Locally Advanced NSCLC
Immunotherapy Expands Treatment Options for Metastatic Bladder Cancer
AML Landscape Rapidly Changing as New Treatment Options Become Available
Dr. Lonial Discusses the Importance of Partnering With a Myeloma Center
